Enzymatic Therapy – Trademark Portfolio

Entity Type: 03

Enzymatic Therapy holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 11 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include CELL FORTE and ESTROBALANCE. The owner is based in Green Bay, WI.

825 Challenger Dr

Green Bay, WI 54311

12 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Enzymatic Therapy's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (11 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

3
Cosmetics & Cleaning (1 filing)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

Frequently Asked Questions

How many trademarks does Enzymatic Therapy have?

Enzymatic Therapy has 12 U.S. trademarks filed with the USPTO. Of these, 2 registered, 9 abandoned, 1 cancelled.

What trademark classes does Enzymatic Therapy file in?

Enzymatic Therapy files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Enzymatic Therapy's most well-known trademarks?

Enzymatic Therapy's registered trademark portfolio includes well-known marks such as CELL FORTE and ESTROBALANCE. These are among 2 currently registered trademarks in the portfolio.

What is Enzymatic Therapy's trademark registration success rate?

Enzymatic Therapy has a 17% trademark registration rate, with 2 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.